This will be a prospective, open-label, 6-week trial of APZ in outpatient children 8-12 years of age with a primary diagnosis of ADHD free of other major psychopathology. The six-week treatment phase will be proceeded by a 1-3 week screening phase.~The study cohort will consist of 10 children with ADHD combined type and 10 children with ADHD predominantly inattentive type who complete the study.~Cognitive measures will be assessed prior to APZ therapy and after 6 weeks of APZ treatment.~Safety assessments and measures of ADHD symptomatology will be collected prior to and during APZ therapy.~While receiving APZ treatment, patients will be seen at baseline, Week 1,2,3,4, and 6.
To look at the cognitive effects of abilify in children with a primary diagnosis of Attention Deficit Hyperactivity Disorder. To examine the safety, effectiveness and tolerability of abilify in children with a primary diagnosis of Attention Deficit Hyperactivity Disorder.